Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000272 |
The purpose of this study is to measure the effect of risperidone in cocaine abusers.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders Substance-Related Disorders |
Drug: Risperidone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | New Approaches to Cocaine Abuse Medications (B) |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, New York | |
Research Foundation for Mental Hygiene | |
New York, New York, United States, 10032 |
Principal Investigator: | Herbert Kleber, M.D. | New York State Psychiatric Institute |
Study ID Numbers: | NIDA-09236-7, P50-09236-7 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000272 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Dopamine Mental Disorders Risperidone |
Substance-Related Disorders Disorders of Environmental Origin Cocaine Serotonin |
Neurotransmitter Agents Disease Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Pathologic Processes Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |